Xencor, Inc Payments for (Proceeds from) Productive Assets
Xencor, Inc (XNCR) reported Payments for (Proceeds from) Productive Assets of $415.00 thousand for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-09.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsForProceedsFromProductiveAssets · last filed 2019-05-09
- Xencor, Inc payments for (proceeds from) productive assets for the quarter ending 2019-03-31 was $415.00K, a 82.31% decline year-over-year.
- Xencor, Inc payments for (proceeds from) productive assets for the quarter ending 2018-03-31 was $2.35M.
| Period end | Payments for (Proceeds from) Productive Assets 3 month | Payments for (Proceeds from) Productive Assets 9 month |
|---|---|---|
| 2019-03-31 | $415.00K 10-Q · filed 2019-05-09 | |
| 2018-09-30 | $4.42M 10-Q · filed 2018-11-05 | |
| 2018-03-31 | $2.35M 10-Q · filed 2019-05-09 | |
| 2017-09-30 | $3.83M 10-Q · filed 2018-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |